A number of firms have modified their ratings and price targets on shares of Acceleron Pharma (NASDAQ: XLRN) recently:

  • 3/2/2018 – Acceleron Pharma had its “buy” rating reaffirmed by analysts at Credit Suisse Group AG. They now have a $55.00 price target on the stock.
  • 3/1/2018 – Acceleron Pharma had its price target raised by analysts at Citigroup Inc from $44.00 to $63.00. They now have a “positive” rating on the stock.
  • 2/28/2018 – Acceleron Pharma had its price target raised by analysts at Barclays PLC from $50.00 to $54.00. They now have an “overweight” rating on the stock.
  • 2/28/2018 – Acceleron Pharma had its price target raised by analysts at Piper Jaffray Companies to $53.00. They now have an “overweight” rating on the stock.
  • 2/28/2018 – Acceleron Pharma had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $62.00 price target on the stock.
  • 2/26/2018 – Acceleron Pharma was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating. They now have a $33.00 price target on the stock.
  • 2/15/2018 – Acceleron Pharma was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 2/2/2018 – Acceleron Pharma was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 1/18/2018 – Acceleron Pharma had its “outperform” rating reaffirmed by analysts at Credit Suisse Group AG. They now have a $55.00 price target on the stock.

Shares of Acceleron Pharma Inc (XLRN) opened at $43.99 on Monday. Acceleron Pharma Inc has a 12 month low of $24.37 and a 12 month high of $46.93. The firm has a market capitalization of $1,997.98, a P/E ratio of -16.29 and a beta of 1.39.

How to Become a New Pot Stock Millionaire

Acceleron Pharma (NASDAQ:XLRN) last released its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.02). The company had revenue of $3.71 million during the quarter, compared to the consensus estimate of $3.39 million. Acceleron Pharma had a negative net margin of 804.49% and a negative return on equity of 38.71%. equities analysts expect that Acceleron Pharma Inc will post -2.5 EPS for the current year.

In related news, SVP Christopher Rovaldi sold 11,000 shares of the stock in a transaction that occurred on Friday, January 12th. The stock was sold at an average price of $45.00, for a total transaction of $495,000.00. Following the sale, the senior vice president now directly owns 35,701 shares in the company, valued at approximately $1,606,545. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Richard F. Pops sold 37,500 shares of the stock in a transaction that occurred on Tuesday, March 6th. The stock was sold at an average price of $41.42, for a total value of $1,553,250.00. Following the sale, the director now owns 68,750 shares in the company, valued at $2,847,625. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 183,521 shares of company stock worth $7,082,848. 3.90% of the stock is owned by corporate insiders.

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Receive News & Ratings for Acceleron Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.